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Résumé en
anglais
BACKGROUND: Surveillance of HIV-1 drug resistance in treated patients with
plasma viral load (VL) >50 copies/mL.
METHODS: The protease and reverse transcriptase (RT) genes were
systematically sequenced in samples from 756 patients with VL >50 copies/mL in
2009. The genotyping results were interpreted for each antiretroviral drug (ARV)
by using the ANRS algorithm v21. Weighted analyses were used to derive
representative estimates of percentages of patients. Prevalence rates were
compared with those obtained in 2004 among patients with VL >1000 copies/mL.
RESULTS: Sequences were obtained for 506 patients. Sequencing was successful
in 45%, 80% and 96% of samples with VL of 51-500, 501-1000 and >1000
copies/mL, respectively. Resistance or possible resistance to at least one ARV was
observed in 59% of samples. Overall, 0.9% of samples contained viruses resistant
to all drugs belonging to at least three drug classes. All resistance prevalence rates
were significantly lower in 2009 than in 2004.
CONCLUSION: In France, where 86% of patients were receiving combination
antiretroviral therapy in 2009, only 15.0% of patients had a VL >50 copies/mL,
suggesting that only 8.9% of treated patients could potentially transmit resistant
viruses. Only 0.08% of patients harboured viruses fully resistant to at least three
antiretroviral drug classes. Further studies are needed to determine whether
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